Lung Cancer Clinical Trials 2026: Targeted Therapy, Immunotherapy & Early Detection

Twenty years ago, a metastatic NSCLC diagnosis meant cytotoxic chemotherapy and a median survival measured in months. The molecular revolution changed that — osimertinib for EGFR-mutant disease, lorlatinib for ALK, sotorasib and adagrasib for KRAS G12C, and pembrolizumab for high PD-L1 expressors have collectively transformed a disease once treated uniformly into molecularly defined subtypes with substantially different prognoses. The 2026 research agenda reflects what those victories also revealed: resistance is inevitable, and roughly a third of patients still lack an actionable driver mutation and don't respond durably to immunotherapy. Those are the hard problems driving the current trial pipeline.

Molecular Subtypes: Why Biomarkers Determine Your Trial Options

NSCLC is classified primarily by molecular driver — adenocarcinoma vs. squamous matters less than EGFR vs. KRAS vs. ALK vs. none. The trial landscape for each subtype is completely distinct:

• EGFR mutations (15–20% of NSCLC): Osimertinib is standard first-line. FLAURA2 showed adding chemotherapy extends median PFS from 16.7 to 25.5 months — meaningful but at the cost of added toxicity, so it's now a calibrated decision for individual patients. Fourth-generation EGFR inhibitors targeting C797S (the resistance mutation that emerges after osimertinib) are in Phase 1/2, including BLU-945 and BBT-176. Combination trials testing fourth-gen + osimertinib upfront are exploring whether you can preempt resistance rather than treat it when it appears.
• KRAS G12C (13% of NSCLC): Sotorasib and adagrasib achieve ORRs of 37–43% in second line, but resistance develops in months via feedback reactivation of RAS pathway signaling. Next-generation KRAS inhibitors — olomorasib and glecirasib — use different binding approaches and are in Phase 2/3. The most rational strategy may be upfront combination: KRAS G12C inhibitor plus SHP2 inhibitor to block the feedback loop, or plus PD-1 inhibitor to combine target therapy with immune activation.
• ALK rearrangements (5%): Lorlatinib is standard first-line after CROWN trial showed 60.2% PFS at 3 years vs. 32.5% for crizotinib. CNS metastases remain the main problem — occurring in 40–50% of patients over time — and current trials focus on combination strategies and next-generation agents for specific lorlatinib-resistance mutations.
• RET, MET exon 14, ROS1, NTRK, BRAF V600E, HER2: All have approved targeted therapies with active trials developing next-generation drugs or extending approved agents to earlier disease stages. Each is a separate research track requiring specific molecular confirmation at enrollment.

Immunotherapy in 2026: Breaking Through the Response Ceiling

For patients without actionable driver mutations, pembrolizumab is standard first-line for PD-L1 ≥50% (ORR ~45%), and chemo-pembrolizumab combinations are used for PD-L1 <50%. The central problem: roughly 50–60% of patients don't achieve durable responses, and there's no reliable predictive biomarker beyond PD-L1 and TMB.

• TIGIT inhibitors: Domvanalimab, tiragolumab, and vibostolimab in Phase 3 combinations with PD-1 inhibitors. Early Phase 2 signals were encouraging, but several Phase 3 trials have returned neutral results. The class hasn't definitively failed — patient selection criteria are being refined for new trials.
• Perioperative immunotherapy (KEYNOTE-671): Pembrolizumab given neoadjuvantly before surgery and adjuvantly after in resectable Stage II–IIIA NSCLC produced 62.4% 24-month EFS vs. 40.6% for chemotherapy alone — a landmark result that's reshaping early-stage treatment. The perioperative design has become the template for multiple ongoing trials.
• Bispecific antibodies: Several bispecific T-cell engagers and bispecific checkpoint inhibitors are in Phase 1/2, targeting PD-1 plus a second checkpoint (LAG-3, TIGIT, TIM-3) in a single molecule. The hypothesis is simultaneous dual blockade produces more sustained T-cell activation than sequential therapy.
• Consolidation after chemoradiation: Durvalumab (PACIFIC) established the standard in Stage III unresectable disease. The LAURA trial showed osimertinib consolidation after chemoradiation in EGFR-mutant Stage III NSCLC produced PFS of 39.1 months vs. 5.6 for placebo — a striking result in this molecularly defined subset.

Small Cell Lung Cancer: Tarlatamab and the T-Cell Engager Era

SCLC is biologically distinct from NSCLC — aggressive, initially chemo-sensitive but rapidly relapsing, without actionable molecular drivers in the traditional sense. For decades, second-line options were essentially topotecan and lurbinectedin — drugs that work briefly in a minority of patients.

Tarlatamab (Imdelltra) changed the equation. This DLL3×CD3 bispecific T-cell engager recruits cytotoxic T cells to DLL3-expressing tumor cells. DLL3 is expressed on 80–85% of SCLC cells and negligibly on normal adult tissues — making it a reasonably tumor-selective target. The DeLLphi-301 trial showed an ORR of 40% and median OS of 14.3 months in patients with at least two prior lines of therapy. FDA accelerated approval followed in May 2024. Phase 3 DeLLphi-304 is testing tarlatamab as first-line maintenance after platinum-based chemotherapy — if positive, it could fundamentally change first-line SCLC care.

Molecular Profiling: What You Need Before Searching for Trials

For lung cancer trial eligibility, comprehensive molecular profiling is non-negotiable — it determines which trials you qualify for. A full workup includes: broad NGS panel (EGFR including exon 20 insertions, KRAS G12C and G12D, ALK, ROS1, RET, MET exon 14 skip, BRAF V600E, NTRK1/2/3, HER2 exon 20); PD-L1 by IHC (22C3 assay); TMB; and liquid biopsy/ctDNA for monitoring and resistance mutation detection when tissue rebiopsy isn't feasible.

Patients with prior tissue biopsy may have an outdated molecular profile — tumors evolve under treatment pressure, and resistance mechanisms driving progression often involve new mutations not present at diagnosis. Many trials require a fresh biopsy within 3–6 months of enrollment. The Lung Cancer Foundation of America's LCFA trial matching service can help translate a complex molecular report into specific trial matches.

Early Detection: Liquid Biopsy and Low-Dose CT Screening Trials

The most transformative potential in lung cancer is detecting it before it becomes metastatic — when surgery offers genuine cure rather than palliation. Lung cancer screening via low-dose CT (LDCT) is recommended by USPSTF for adults 50–80 with a 20 pack-year smoking history who currently smoke or quit within the past 15 years, but uptake has been substantially below the eligible population. Trials in 2026 are addressing two distinct gaps.

The first is broadening screening eligibility. The National Lung Screening Trial (NLST) and NELSON trial established LDCT screening in high-risk current and former smokers. But lung cancer also occurs in never-smokers — accounting for 10–15% of cases in the US and a higher proportion in Asian women — and in smokers who don't meet current age/pack-year criteria. Studies like LungSEARCH and UKLS are evaluating risk-stratified screening models that incorporate biomarkers, CT phenotyping, and demographic risk factors to identify who within the broader population benefits from screening.

The second is using liquid biopsy — circulating tumor DNA (ctDNA) from blood — as a screening and monitoring tool. Grail's Galleri multi-cancer early detection test has generated Phase 3 data showing it can detect lung cancer signal from a blood draw, sometimes before imaging-detectable disease. The NHS-Galleri trial is the largest prospective study of this approach, with 140,000 participants. Clinical integration is still 3–5 years away for most populations, but the proof-of-concept that ctDNA can find cancer earlier than conventional symptoms or standard screening is now demonstrated.

For patients on active treatment, ctDNA monitoring offers earlier detection of molecular resistance than standard imaging-based progression criteria, allowing earlier transition to next-line therapy or trial enrollment while performance status remains adequate.

Who Qualifies for Lung Cancer Trials: Common Eligibility Patterns

Eligibility requirements vary significantly by trial phase and treatment type, but several patterns apply broadly across the landscape:

• ECOG performance status 0–1 for most Phase 2/3 trials. Some Phase 1 trials accept PS 2. Patients with ECOG PS 3–4 are typically ineligible for interventional trials, though observational and supportive care studies may enroll them.
• Documented molecular profiling. Without a confirmed driver mutation or PD-L1 score, enrollment in the relevant biomarker-selected trials is not possible. Many sites offer rapid NGS turnaround specifically for trial eligibility assessment.
• Adequate organ function. Standard thresholds: ANC ≥1.5×10⁹/L, platelets ≥100×10⁹/L, creatinine ≤1.5×ULN or calculated CrCl ≥30–60 mL/min (varies), total bilirubin ≤1.5×ULN, ALT/AST ≤2.5×ULN (or ≤5×ULN if liver metastases). These thresholds matter most in patients with hepatic or renal compromise and are worth checking before pursuing a specific trial.
• Prior therapy line requirements. Second-line ADC trials require prior platinum and checkpoint inhibitor therapy. First-line combination trials require no prior systemic treatment. De novo enrollment in the wrong treatment-line trial is the most common avoidable eligibility error.
• Brain metastases. Historically an exclusion criterion, many 2026 trials specifically allow stable, treated brain metastases — reflecting the clinical reality that 25–40% of NSCLC patients will develop CNS disease. Always confirm the protocol's specific brain metastases criteria rather than assuming exclusion.

Frequently Asked Questions